Purple Biotech (PPBT) Other Operating Expenses (2017 - 2025)
Purple Biotech's (PPBT) quarterly Other Operating Expenses came in at $20.5 million in Q4 2025, up 10039.6% quarter-over-quarter from $202000.0 in Q2 2024.
Powered by 
Analysis
Purple Biotech (PPBT) Other Operating Expenses (2017 - 2025) Analysis & Trends
Purple Biotech (PPBT) has reported Other Operating Expenses for 5 consecutive years, with $20.5 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $20.5 million in Q4 2025; TTM through Jun 2026 was $20.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $20.4 million, up 14487.86% from the prior year.
- Other Operating Expenses was $20.5 million for Q4 2025 at Purple Biotech, up from $202000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $20.5 million in Q4 2025 and troughed at $202000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Purple Biotech | 286,924.75 | 228,924.75 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 20.48 Mn |
| Jun 30, 2024 | 202,000.00 |
| Dec 31, 2019 | -166,000.00 |
| Dec 31, 2018 | -771,000.00 |
| Dec 31, 2017 | 3.77 Mn |